The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| IXHL | -84.04% | N/A | N/A | -99% |
| S&P | +11% | +85.61% | +13.15% | +51% |
Incannex Healthcare Ltd. is a clinical stage pharmaceutical development company, which engages in the research and development associated with medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It operates through the following segments: Psychedelic Products, Cannabinoid Products, and Corporate. The Psychedelic Products segment is involved in the use of psychedelic medicine and therapies for the treatment of mental health disorders. The Cannabinoid Products segment focuses on the use of medicinal cannabinoid products. The Corporate segment consists of management of the organization, capital management, and management of resources. The company was founded on April 27, 2001 and is headquartered in Melbourne, Australia.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | -100.0% |
| Gross Profit | -$0.07M | -944.4% |
| Gross Margin | -931.80% | 0.0% |
| Market Cap | $43.50M | -95.0% |
| Market Cap / Employee | $3.63M | 0.0% |
| Employees | 12 | 33.3% |
| Net Income | -$6.41M | -18.2% |
| EBITDA | -$6.73M | -8.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $73.28M | 1920.4% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.06M | -71.0% |
| Short Term Debt | $0.15M | -23.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -101.03% | 0.0% |
| Return On Invested Capital | -141.85% | -45.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$9.17M | -317.9% |
| Operating Free Cash Flow | -$9.16M | -317.8% |
| Metric | Q4 2024 | Q1 2025 | Q1 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 141.78 | 111.69 | 111.69 | 6.74 | -90.43% |
| Price to Sales | 381.26 | 135.52 | 151.58 | 12006.40 | 2840.97% |
| Price to Tangible Book Value | 141.78 | 111.69 | 111.69 | 6.74 | -90.43% |
| Enterprise Value to EBITDA | -7.78 | -1.37 | 0.23 | -10.55 | 104.76% |
| Return on Equity | -240.0% | -201.9% | -381.1% | -114.5% | - |
| Total Debt | $4.10M | $1.69M | $0.26M | $0.21M | -48.91% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
